/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR
DISSEMINATION IN THE UNITED STATES/
The Canadian National Stock Exchange has not approved nor disapproved
the contents of this press release.
VANCOUVER, April 5 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") is pleased to announce that it has entered
into an advisory services agreement (the "Agreement") with Sandra
Broccoli, CA, for the provision of advisory services to the Company's
management and board of directors. Ms. Broccoli is currently the
Corporate Controller of Liz Claiborne Canada Inc., and the past
Director of Corporate Services of Smith & Nephew Inc. in Canada where
she led the direction of the Corporate Finance, Contracts & Tenders
departments. Smith & Nephew is one of the world's largest wound care
management companies with over 9,000 employees and over $3.5 billion in
During her 11 years of service at Smith & Nephew, Ms. Broccoli
established new product launch teams, expedited time to market and
empowered the company's National sales team. She was also responsible
for contract pricing strategy in collaboration with Sales and Marketing
management in line with corporate sales and profit goals. Prior to
joining Smith & Nephew, Ms. Broccoli was the tax manager and an auditor
at Ernst & Young, LLP for 7 years.
Ms. Broccoli has a graduate degree in Public Accountancy from the
University of McGill as well as a Chartered Accountant (CA) designation
from the Quebec Order of Chartered Accountants.
About Merus Labs International Inc.
Merus is a specialty pharmaceutical company engaged in the acquisition
and licensing of pharmaceutical products. The Company utilizes its
expertise in the North American pharmaceutical markets and its access
to capital to acquire and license niche branded products in Canada and
United States. Merus further enhances the sale and distribution of
these products by introduction of a focused marketing and promotion
This press release may contain forward-looking statements that involve
risks and uncertainties. These statements relate to future events or
our future financial performance. In some cases, you can identify
forward-looking statements by terminology including "could", "may",
"will", "should", "expect", "plan", "anticipate", "believe",
"estimate", "predict", "potential" and the negative of these terms or
other comparable terminology. While these forward-looking statements,
and any assumptions upon which they are based, are made in good faith
and reflect our current judgment regarding the direction of our
business, actual results will almost always vary, sometimes materially,
from any estimates, predictions, projections, assumptions or other
future performance suggested in this report. Except as required by
applicable law, we do not intend to update any of the forward-looking
statements so as to conform these statements to actual results.
Investors should refer to the risks disclosed in the Company's reports
filed from time to time with securities regulatory authorities.
SOURCE Merus Labs International Inc.
For further information:
Dr. Ahmad Doroudian, Chief Executive Officer
Merus Labs International Inc.
Tel: (604) 805-7783